These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

141 related items for PubMed ID: 18808741

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Current evidence and therapeutic strategies for multiple sclerosis.
    Wingerchuk DM.
    Semin Neurol; 2008 Feb; 28(1):56-68. PubMed ID: 18256987
    [Abstract] [Full Text] [Related]

  • 23. [Mitoxantrone].
    Pericot I, Montalban X.
    Neurologia; 2003 Feb; 18(6):318-23. PubMed ID: 12838451
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Immunomodulatory therapies for relapsing-remitting multiple sclerosis: monoclonal antibodies, currently approved and in testing.
    Craddock J, Markovic-Plese S.
    Expert Rev Clin Pharmacol; 2015 May; 8(3):283-96. PubMed ID: 25916665
    [Abstract] [Full Text] [Related]

  • 26. [Selected issues of immunomodulating treatment in multiple sclerosis].
    Cendrowski W.
    Neurol Neurochir Pol; 2004 May; 38(4):299-306. PubMed ID: 15383958
    [Abstract] [Full Text] [Related]

  • 27. Daclizumab in treatment of multiple sclerosis patients.
    Ali EN, Healy BC, Stazzone LA, Brown BA, Weiner HL, Khoury SJ.
    Mult Scler; 2009 Feb; 15(2):272-4. PubMed ID: 19136546
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. A randomized crossover study of bee sting therapy for multiple sclerosis.
    Wesselius T, Heersema DJ, Mostert JP, Heerings M, Admiraal-Behloul F, Talebian A, van Buchem MA, De Keyser J.
    Neurology; 2005 Dec 13; 65(11):1764-8. PubMed ID: 16221950
    [Abstract] [Full Text] [Related]

  • 30. [Therapy of multiple sclerosis].
    Simó M.
    Neuropsychopharmacol Hung; 2009 Mar 13; 11(1):23-6. PubMed ID: 19731815
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Alemtuzumab for the treatment of relapsing-remitting multiple sclerosis: a review of its clinical pharmacology, efficacy and safety.
    Jones DE, Goldman MD.
    Expert Rev Clin Immunol; 2014 Oct 13; 10(10):1281-91. PubMed ID: 25148422
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Anti-CD25 (daclizumab) monoclonal antibody therapy in relapsing-remitting multiple sclerosis.
    Martin R.
    Clin Immunol; 2012 Jan 13; 142(1):9-14. PubMed ID: 22284868
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. [Immunomodulatory therapy in multiple sclerosis].
    Csépány T, Bereczki D.
    Ideggyogy Sz; 2004 Nov 20; 57(11-12):401-16. PubMed ID: 15662768
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.